Low-dose hydrochlorothiazide in the therapeutic strategy of hypertension: focus on the preserved metabolic profile

2011 ◽  
Author(s):  
Roland G. Asmar ◽  
Jennifer T. Asmar
Keyword(s):  
Metabolic Profile ◽  
Therapeutic Strategy ◽  
Low Dose

Increased Thromboxane Biosynthesis in Essential Thrombocythemia

1995 ◽  
Vol 74 (05) ◽  
pp. 1225-1230 ◽  
Author(s):  
Bianca Rocca ◽  
Giovanni Ciabattoni ◽  
Raffaele Tartaglione ◽  
Sergio Cortelazzo ◽  
Tiziano Barbui ◽  
...  
Keyword(s):  
Platelet Count ◽  
Platelet Activation ◽  
Essential Thrombocythemia ◽  
Therapeutic Strategy ◽  
Low Dose ◽  
Thrombotic Risk ◽  
Dose Aspirin ◽  
Gender And Age ◽  
Low Dose Aspirin

SummaryIn order to investigate the in vivo thromboxane (TX) biosynthesis in essential thromboeythemia (ET), we measured the urinary exeretion of the major enzymatic metabolites of TXB2, 11-dehydro-TXB2 and 2,3-dinor-TXB2 in 40 ET patients as well as in 26 gender- and age-matched controls. Urinary 11-dehydro-TXB2 was significantly higher (p <0.001) in thrombocythemic patients (4,063 ± 3,408 pg/mg creatinine; mean ± SD) than in controls (504 ± 267 pg/mg creatinine), with 34 patients (85%) having 11-dehydro-TXB2 >2 SD above the control mean. Patients with platelet number <1,000 × 109/1 (n = 25) had significantly higher (p <0.05) 11 -dehydro-TXB2 excretion than patients with higher platelet count (4,765 ± 3,870 pg/mg creatinine, n = 25, versus 2,279 ± 1,874 pg/mg creatinine, n = 15). Average excretion values of patients aging >55 was significantly higher than in the younger group (4,784 ± 3,948 pg/mg creatinine, n = 24, versus 2,405 ± 1,885 pg/mg creatinine, n = 16, p <0.05). Low-dose aspirin (50 mg/d for 7 days) largely suppressed 11-dehydro-TXB2 excretion in 7 thrombocythemic patients, thus suggesting that platelets were the main source of enhanced TXA2 biosynthesis. The platelet count-corrected 11-dehydro-TXB2 excretion was positively correlated with age (r = 0.325, n = 40, p <0.05) and inversely correlated with platelet count (r = -0.381, n = 40, p <0.05). In addition 11 out of 13 (85%) patients having increased count-corrected 11-dehydro-TXB2 excretion, belonged to the subgroup with age >55 and platelet count <1,000 × 1099/1. We conclude that in essential thrombocythemia: 1) enhanced 11-dehydro-TXB2 excretion largely reflects platelet activation in vivo;2) age as well as platelet count appear to influence the determinants of platelet activation in this setting, and can help in assessing the thrombotic risk and therapeutic strategy in individual patients.

Thiamme2-G, A Novel O-GlcNAcase Inhibitor, Reduces Tau Hyperphosphorylation and Rescues Cognitive Impairment in Mice

2021 ◽  
pp. 1-14
Author(s):  
Danmin Pan ◽  
Jin-Hua Gu ◽  
Jin Zhang ◽  
Yae Hu ◽  
Fei Liu ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Low Dose ◽  
Body Weight Loss ◽  
Synaptic Proteins ◽  
Novel Object Recognition ◽  
Low Doses ◽  
Tau Hyperphosphorylation ◽  
Protein Tau ◽  
Abnormal Hyperphosphorylation ◽  
Brain Changes

Background: Abnormal hyperphosphorylation of microtubule-associated protein tau plays a pivotal role in Alzheimer’s disease (AD). We previously found that O-GlcNAcylation inversely correlates to hyperphosphorylation of tau in AD brain, and downregulation of brain O-GlcNAcylation promotes tau hyperphosphorylation and AD-like neurodegeneration in mice. Objective: Herein we investigated the effect of increasing O-GlcNAcylation by using intermittent dosing with low doses of a potent novel O-GlcNAcase (OGA) inhibitor on AD-like brain changes and cognitive function in a mouse model of sporadic AD (sAD) induced by intracerebroventricular (ICV) injection of streptozotocin (STZ). Methods: STZ was injected into the lateral ventricle of C57BL/6J mice. From the second day, Thiamme2-G (TM2G) or saline, as a vehicle control, was orally administered to the ICV-STZ mice three times per week for five weeks. A separate group of ICV-saline mice treated with saline was used as a baseline control. Behavioral tests, including open field and novel object recognition, were conducted three weeks after the first dose of the TM2G or saline. Protein O-GlcNAcylation, tau hyperphosphorylation, synaptic proteins, and neuroinflammation in the mouse brain were assessed by western blotting. Results: ICV-STZ caused decreased protein O-GlcNAcylation. Enhancement of O-GlcNAcylation to moderate levels by using low-dose OGA inhibitor in ICV-STZ mice prevented STZ-induced body weight loss, rescued cognitive impairments, and restored AD-like pathologies, including hyperphosphorylation of tau and abnormalities in synaptic proteins and neuroinflammation. Conclusion: These findings suggest that moderately increasing protein O-GlcNAcylation by using low doses of OGA inhibitor may be a suitable therapeutic strategy for sAD.

Metabolic profile of a continuous versus a cyclic low-dose combined oral contraceptive after one year of use

2011 ◽  
Vol 16 (2) ◽  
pp. 85-94 ◽  
Author(s):  
Mandana Rad ◽  
Cornelis Kluft ◽  
Marieke L. de Kam ◽  
Piet Meijer ◽  
Adam F. Cohen ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Metabolic Profile ◽  
Low Dose ◽  
Combined Oral Contraceptive ◽  
One Year

scholarly journals Eicosapentaenoic Acid Based Therapies: Fish Facts and Stories

2020 ◽  
pp. 1-9
Author(s):  
Aravind Reddy Kuchkuntla ◽  
◽  
Sri Harsha Patllola ◽  
Keyword(s):  
Eicosapentaenoic Acid ◽  
Inflammatory Markers ◽  
Metabolic Profile ◽  
Low Dose ◽  
Coronary Plaque ◽  
High Dose ◽  
Preventive Cardiology ◽  
Cardio Protection ◽  
Cvd Prevention ◽  
Coronary Events

The significant hypo-lipidemic, anti-thrombotic and anti-inflammatory features of EPA created extensive interest in preventive cardiology from the early 90s, since then several clinical studies were conducted to study the mechanisms and benefits of fish oil use. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are essential FAs therefore, they must be provided in diet or in the form of supplements. The supplements are low dose combinations of EPA and DHA have no significant benefits in terms of CVD prevention in clinical trials. However, a high dose Ethyl ester formulation of EPA has shown a 25% reduction of major adverse coronary events in the secondary prevention. Cardio-protective potential of EPA is attributed to its triglyceride lowering effect, reduction in inflammatory markers, improving coronary plaque stability, anti-platelet effect and improvements of over-all metabolic profile. We intend to provide preventive and therapeutic potentials of EPA in CVD, mechanisms of cardio protection, available evidence and future trails.

Combination Oral Prednisone and Intravenous Immunoglobulin in the Treatment of Scleromyxedema

2005 ◽  
Vol 9 (3) ◽  
pp. 99-104 ◽  
Author(s):  
Candace Majeski ◽  
Muba Taher ◽  
Parbeer Grewal ◽  
Marlene Dytoc ◽  
Gilles Lauzon
Keyword(s):  
Intravenous Immunoglobulin ◽  
Therapeutic Strategy ◽  
Low Dose ◽  
Treatment Options ◽  
Oral Prednisone ◽  
Immune Disorders ◽  
Review Of The Literature ◽  
Condition Optimization ◽  
Dose Oral ◽  
Systemic Manifestations

Background: Scleromyxedema is a clinical variant of the rare disease papular mucinosis that has both cutaneous and systemic manifestations. Treatment options are numerous and tend to be associated with serious potential side effects and frequent relapse. Objective: We report a case of scleromyxedema treated with low-dose oral prednisone and intravenous immunoglobulin (IVIg). This is followed by a review of the literature. Conclusion: IVIg is being used for a growing number of inflammatory and immune disorders. It is being increasingly reported as a successful treatment for scleromyxedema. Although our patient succumbed to the disease, combination therapy with prednisone and IVIg provided temporary symptomatic, laboratory, and clinical improvement of the condition. Optimization of this therapeutic strategy is thus indicated for the management of scleromyxedema.

Combined therapy with Xuezhikang and low-dose rosuvastatin provides an effective and safe therapeutic strategy for dyslipidemic patients

2015 ◽  
Vol 10 (3) ◽  
pp. 243-250 ◽  
Author(s):  
Min Wang ◽  
Shui-Ping Zhao ◽  
Ming-Yue Tan ◽  
Fang Huang
Keyword(s):  
Therapeutic Strategy ◽  
Low Dose ◽  
Combined Therapy

Therapeutic strategy using low-dose carperitide in patients with acute heart failure

2020 ◽  
Vol 35 (12) ◽  
pp. 1767-1768
Author(s):  
Masataka Kamiya ◽  
Naoki Sato ◽  
Wataru Shimizu
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Therapeutic Strategy ◽  
Low Dose
Sign in / Sign up

Export Citation Format

Share Document